Multifactorial Approach for Depression in Multiple Endocrine Neoplasia 2A (MEN2A): A Case Report

Why It Matters

Recognizing the intertwined endocrine and psychiatric factors in MEN2A prevents misdiagnosis and ensures comprehensive care, improving patient outcomes and informing future treatment guidelines.

Key Takeaways

• MEN2A patients face endocrine‑related mood disturbances
• Prophylactic thyroidectomy can trigger long‑term psychiatric symptoms
• Multidisciplinary assessment essential before psychiatric medication
• Family history amplifies depression risk in MEN2A

Pulse Analysis

Multiple endocrine neoplasia type 2A (MEN2A) is a rare autosomal‑dominant syndrome driven by RET proto‑oncogene mutations. Affected individuals develop medullary thyroid carcinoma, hyperparathyroidism, and pheochromocytoma in varying combinations, with prevalence around 1 in 40,000 in the United States. While the oncologic and surgical challenges of MEN2A are well documented, psychiatric sequelae have received far less attention. Hormonal imbalances—particularly hypothyroidism after prophylactic thyroidectomy, calcium dysregulation from hyperparathyroidism, and catecholamine excess from pheochromocytoma—can all perturb neurotransmitter systems, predisposing patients to depression, anxiety, and even psychosis.

The reported case of a 21‑year‑old male illustrates how these endocrine disturbances intersect with psychosocial stressors to produce severe depressive illness. After childhood prophylactic thyroidectomy, the patient required lifelong levothyroxine, yet suboptimal replacement can mimic depressive symptoms. Concurrent hyperparathyroidism and a history of pheochromocytoma further complicate mood regulation through calcium‑mediated monoamine changes and episodic blood‑pressure spikes. Adding a family history of MEN2A‑related depression and personal guilt over past misconduct created a layered etiologic picture. Targeted treatment—optimizing hormone levels, sertraline, risperidone, and structured psychotherapy—proved effective, underscoring the need to address each contributing factor.

For clinicians, the case signals that psychiatric evaluation in MEN2A must begin with a thorough endocrine work‑up. Routine screening of thyroid function, parathyroid hormone, calcium, and catecholamine markers can differentiate hormone‑driven mood changes from primary psychiatric disorders, guiding appropriate pharmacologic choices. A multidisciplinary team that includes endocrinologists, psychiatrists, and psychotherapists can coordinate hormone replacement, surgical interventions, and mental‑health support, reducing the risk of misdiagnosis and unnecessary medication. As genetic counseling reveals intergenerational vulnerability, future research should explore standardized protocols for mental‑health monitoring in MEN2A families, potentially improving outcomes and quality of life.